Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Share-based Compensation (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Share-based Compensation for 16 consecutive years, with $700000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation fell 39.76% to $700000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $3.0 million, a 28.34% decrease, with the full-year FY2024 number at $4.1 million, up 50.31% from a year prior.
  • Share-based Compensation was $700000.0 for Q3 2025 at Xtant Medical Holdings, down from $742000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $1.2 million in Q2 2024 to a low of $439000.0 in Q2 2023.
  • A 5-year average of $721105.3 and a median of $700000.0 in 2025 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: soared 173.35% in 2024, then crashed 39.76% in 2025.
  • Xtant Medical Holdings' Share-based Compensation stood at $708000.0 in 2021, then decreased by 9.75% to $639000.0 in 2022, then skyrocketed by 46.79% to $938000.0 in 2023, then fell by 12.9% to $817000.0 in 2024, then dropped by 14.32% to $700000.0 in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Share-based Compensation are $700000.0 (Q3 2025), $742000.0 (Q2 2025), and $758000.0 (Q1 2025).